U.S. markets open in 3 hours 38 minutes

Heat Biologics, Inc. (HTBX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.9000-0.0700 (-2.36%)
At close: 04:00PM EST
2.9900 +0.09 (+3.10%)
After hours: 05:48PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close2.9700
Bid0.0000 x 2200
Ask0.0000 x 2900
Day's Range2.8700 - 2.9800
52 Week Range2.8700 - 17.0000
Avg. Volume291,398
Market Cap73.67M
Beta (5Y Monthly)0.20
PE Ratio (TTM)N/A
EPS (TTM)-1.1520
Earnings DateNov 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for HTBX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Heat Biologics, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features our annual pharmaceutical pipeline, a fresh look at Barry Callebaut's chocolate operation, the buzz around RingCentral, and SAP, Subsea 7, and Just Eat Takeaway.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • Zacks Small Cap Research

    HTBX: RapidVax Unveiled; Elusys Acquisition

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Since Our Last Update Since our last update, Heat Biologics, Inc. (NASDAQ:HTBX) has announced several major developments including the unveiling of Heat’s RapidVax novel cellular vaccine platform, a planned acquisition of Elusys Therapeutics, and new PTX-35 preclinical data in organ transplantation. Heat also looks forward

  • Benzinga

    Heat Biologics Issues New PTX-35 Preclinical Data In Organ Transplantation, Update On HS-110

    Heat Biologics Inc (NASDAQ: HTBX) announced promising preclinical data regarding PTX-35. The data has been accepted for publication in the American Journal of Transplantation. A single dose of the preclinical version of PTX-35 (mPTX-35) expanded regulatory T cells (Tregs) and significantly improved disease and graft survival outcomes. Chemically induced pancreatic failure (a model for type-1 diabetes) could be partially reversed when mice were transplanted with beta-cell islet allografts and tre

  • GlobeNewswire

    Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

    Data demonstrates that PTX-35 may have utility in solid organ transplantation, and to potentially slow or mitigate deleterious immune responses where self-tissue tolerance is impairedDURHAM, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced promising new preclinical data regarding PTX-35 has been accepted for publication in t